Patents by Inventor Atsushi Imaizumi
Atsushi Imaizumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11986530Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.Type: GrantFiled: April 27, 2020Date of Patent: May 21, 2024Assignees: THERABIOPHARMA INC., KYOTO UNIVERSITYInventors: Hideaki Kakeya, Masashi Kanai, Nobuaki Takahashi, Tadashi Hashimoto, Atsushi Imaizumi, Hitomi Ozawa
-
Patent number: 11911348Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: October 9, 2020Date of Patent: February 27, 2024Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Publication number: 20240000723Abstract: Provided is an agent or a food composition capable of decreasing a neutrophil-to-lymphocyte ratio. An agent for decreasing a neutrophil-to-lymphocyte ratio in blood contains a curcumin as an active ingredient.Type: ApplicationFiled: November 12, 2021Publication date: January 4, 2024Applicants: THERABIOPHARMA INC., NATIONAL HOSPITAL ORGANIZATIONInventors: Koji HASEGAWA, Tadashi HASHIMOTO, Atsushi IMAIZUMI, Tatsuya OGAWA, Hitomi UMETA, Atsuhiro KISHIMOTO
-
Publication number: 20230265118Abstract: Provided are a derivative of curcumin monoglucuronide excellent in solubility and chemical stability, which can be provided as pharmaceuticals, and a method for producing the same. A salt of curcumin monoglucuronide represented by Chemical Formula 1, wherein M represents a pharmaceutically acceptable cation, a hydrate thereof, or a solvate thereof.Type: ApplicationFiled: July 2, 2021Publication date: August 24, 2023Applicant: THERABIOPHARMA INC.Inventors: Atsushi IMAIZUMI, Hitomi UMETA, Yasumichi FUKUDA
-
Publication number: 20210023025Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: ApplicationFiled: October 9, 2020Publication date: January 28, 2021Applicant: THERAVALUES CORPORATIONInventors: Yutaka KAWAKAMI, Tomonori YAGUCHI, Taeko HAYAKAWA, Atsushi IMAIZUMI
-
Patent number: 10849862Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: December 24, 2015Date of Patent: December 1, 2020Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Publication number: 20200254105Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.Type: ApplicationFiled: April 27, 2020Publication date: August 13, 2020Applicants: THERABIOPHARMA INC., KYOTO UNIVERSITYInventors: Hideaki KAKEYA, Masashi Kanai, Nobuaki Takahashi, Tadashi Hashimoto, Atsushi Imaizumi, Hitomi Ozawa
-
Publication number: 20190224325Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.Type: ApplicationFiled: June 28, 2017Publication date: July 25, 2019Applicants: THERABIOPHARMA INC., KYOTO UNIVERSITYInventors: Hideaki KAKEYA, Masashi KANAI, Nobuaki TAKAHASHI, Tadashi HASHIMOTO, Atsushi IMAIZUMI, Hitomi OZAWA
-
Patent number: 10245238Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.Type: GrantFiled: May 14, 2015Date of Patent: April 2, 2019Assignees: THERAVALUES CORPORATIONInventors: Hirofumi Takeuchi, Kohei Tahara, Atsushi Imaizumi, Tsukasa Takahashi, Takato Matsui, Hitomi Ozawa
-
Publication number: 20170367997Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: ApplicationFiled: December 24, 2015Publication date: December 28, 2017Applicant: THERABIOPHARMA INC.Inventors: Yutaka KAWAKAMI, Tomonori YAGUCHI, Taeko HAYAKAWA, Atsushi IMAIZUMI
-
Publication number: 20170239194Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.Type: ApplicationFiled: May 14, 2015Publication date: August 24, 2017Applicants: THERAVALUES CORPORATIONInventors: Hirofumi TAKEUCHI, Kohei TAHARA, Atsushi IMAIZUMI, Tsukasa TAKAHASHI, Takato MATSUI, Hitomi OZAWA
-
Patent number: 7163933Abstract: To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.Type: GrantFiled: February 21, 2003Date of Patent: January 16, 2007Assignee: Teijin LimitedInventors: Seiichi Ishizuka, Kazuya Takenouchi, Atsushi Imaizumi, Yasuhiro Oue, Noriyoshi Kurihara, Sakamuri V. Reddy, G. David Roodman
-
Publication number: 20050165094Abstract: Compounds for use in the treatment of heart disease include a superoxide scavenger and an organic nitrate or nitrite moiety. The compounds can be represented by the formula (A)n(B)m, in which A is a superoxide scavenger, B is an organic nitrate or organic nitrite moiety, and n and m are values between 1 and 8. These compounds do not suffer from the problem of patient tolerance that is associated with the use of conventional agents such as organic nitrates.Type: ApplicationFiled: May 18, 2001Publication date: July 28, 2005Inventors: Zhi Zhang, Declan Naughton, Yoshihiko Sumi, Atsushi Imaizumi
-
Publication number: 20040019024Abstract: To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist.Type: ApplicationFiled: August 4, 2003Publication date: January 29, 2004Inventors: Seiichi Ishizuka, Kazuya Takenouchi, Atsushi Imaizumi, Yasuhiro Oue, Noriyoshi Kurihara, Sakamuri V Reddy, G. David Roodman
-
Publication number: 20040018985Abstract: A glutathione derivative having a dramatically enhanced hematopoiesis promoting effect in the living body, said derivative being represented by the formula (I): 1Type: ApplicationFiled: July 21, 2003Publication date: January 29, 2004Applicant: TEIJIN LIMITEDInventors: Kiyoyuki Sakon, Yoshimitsu Naniwa, Mitsuru Kobayashi, Daishiro Miura, Hiroshi Imai, Atsushi Imaizumi
-
Publication number: 20030191094Abstract: To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.Type: ApplicationFiled: February 21, 2003Publication date: October 9, 2003Applicant: TEIJIN LIMITEDInventors: Seiichi Ishizuka, Kazuya Takenouchi, Atsushi Imaizumi, Yasuhiro Oue, Noriyoshi Kurihara, Sakamuri V. Reddy, G. David Roodman
-
Patent number: 6627732Abstract: The present invention provides a glutathione derivative having a dramatically enhanced hematopoiesis promoting effect in the living body represented by the formula (I): where A represents H or a C1-C20 acyl group; R1 represents a C1-C26 alkyl group or a C3-C26 alkenyl group; and R2 represents H, a C1-C26 alkyl group or a C3-C26 alkyl group, with the proviso that compounds are excluded in which R1 is a C1-C10 alkyl group or a C3-C10 alkenyl group, and simultaneously R2 is H, a C1-C10 alkyl group or a C3-C10 alkenyl group. The present invention also provides a salt of the glutathione derivative, or a colloidal composition that enables the safe and effective development of the effects of the glutathione derivative in the living body.Type: GrantFiled: October 16, 2000Date of Patent: September 30, 2003Assignee: Teijin LimitedInventors: Kiyoyuki Sakon, Yoshimitsu Naniwa, Mitsuru Kobayashi, Daishiro Miura, Hiroshi Imai, Atsushi Imaizumi
-
Patent number: 6346634Abstract: Compounds for use in the treatment of heart disease include a superoxide scavenger and an organic nitrate or nitrite moiety. The compounds can be represented by the formula (A)n(B)m, in which A is a superoxide scavenger, B is an organic nitrate or organic nitrite moiety, and n and m are values between 1 and 8. These compounds do not suffer from the problem of patient tolerance that is associated with the use of conventional agents such as organic nitrates.Type: GrantFiled: May 1, 2000Date of Patent: February 12, 2002Assignee: Teijin LimitedInventors: Zhi Zhang, Declan P. Naughton, Yoshihiko Sumi, Atsushi Imaizumi
-
Patent number: 5851983Abstract: The present invention provides an elastase inhibitory polypeptide comprising a C-terminal half of a human secretory leukocyte protease inhibitor (SLPI) and having an elastase inhibitory activity wherein inhibitory activity of a trypsin-like serine protease does not exceed 1/10 of elastase inhibitory activity, and polypeptides having the above-mentioned biological activity wherein one or more than one amino acid is added, one or more than one amino acid is deleted and/or one or more than one amino acid is replaced. The present invention also provides a process for the production of the above-mentioned protein or other protein via a corresponding fused protein.Type: GrantFiled: October 20, 1992Date of Patent: December 22, 1998Assignee: Teijin LimitedInventors: Takashi Sugiyama, Takashi Kamimura, Kenichi Masuda, Masahiro Okada, Eiko Ohtsuka, Atsushi Imaizumi, Kunihito Watanabe, Tetsuya Suga, Yohichi Matsumoto, Akiko Takeuchi
-
Patent number: 5374713Abstract: Peptide inhibitors of phospholipase A.sub.2 from inflammatory sites having the amino acid sequence given in formula SEQ. I.D.Type: GrantFiled: June 18, 1992Date of Patent: December 20, 1994Assignee: Teijin LimitedInventors: Yorimasa Suwa, Atsushi Imaizumi, Masahiro Okada, Chieko Azuma, Ichiro Kudo, Keizo Inoue